Pfizer buries data showing mRNA flu vaccine bombed in trial with elderly, not much better under 65 | Just The News

More than a year after its promised deadline to investors, drugmaker puts alarming results in federal government's "virtual filing cabinet" and touts absolute difference of 0.32% for non-elderly adults in prestigious journal. - Greg Piper

The results are finally in: 

Compared to a standard flu shot, the mRNA vaccine was 

• associated with six times as many adverse events as infections prevented in adults under 65, and 
• it outright failed in elderly people, associated with more deaths and both minor and serious injuries, from injection-site swelling to kidney problems.

The company buried the long-delayed elderly results on the government's clinical trials website this spring, more than a year late and without announcing them to the public or investors, and gave an optimistic take on the under-65 results in the New England Journal of Medicine last week, while admitting the mRNA shot was "associated with more reactogenicity events."...